MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 5,000 Shares

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $4.41, for a total value of $22,050.00. Following the transaction, the director now directly owns 120,583 shares in the company, valued at $531,771.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Friday, January 26th, John Joseph Johnston sold 5,000 shares of MaxCyte stock. The stock was sold at an average price of $5.12, for a total value of $25,600.00.

MaxCyte Trading Down 3.0 %

MXCT stock traded down $0.13 during trading on Thursday, reaching $4.19. The stock had a trading volume of 609,632 shares, compared to its average volume of 678,650. The stock’s 50 day moving average is $4.64 and its two-hundred day moving average is $4.20. The firm has a market cap of $436.18 million, a PE ratio of -11.27 and a beta of 1.36. MaxCyte, Inc. has a 52 week low of $2.45 and a 52 week high of $5.55.

Institutional Trading of MaxCyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new stake in MaxCyte in the second quarter worth about $27,000. PNC Financial Services Group Inc. purchased a new stake in shares of MaxCyte during the fourth quarter worth about $29,000. Victory Capital Management Inc. purchased a new stake in shares of MaxCyte during the third quarter worth about $31,000. Johnson Investment Counsel Inc. purchased a new stake in shares of MaxCyte during the third quarter worth about $34,000. Finally, Tower Research Capital LLC TRC grew its position in shares of MaxCyte by 139.8% during the first quarter. Tower Research Capital LLC TRC now owns 7,108 shares of the company’s stock worth $35,000 after purchasing an additional 4,144 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on MXCT shares. William Blair reissued an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th. BTIG Research dropped their target price on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Craig Hallum assumed coverage on MaxCyte in a report on Wednesday, November 29th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Stephens reaffirmed an “overweight” rating and set a $11.00 price target on shares of MaxCyte in a report on Wednesday, March 13th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.